Showing posts with label Discovery. Show all posts
Showing posts with label Discovery. Show all posts

Monday, June 13, 2022

U.S. Court of Appeals for the Federal Circuit, University of Massachusetts v. L’Oréal S.A., Docket No. 2021-1969

Jurisdictional Discovery

 

Personal Jurisdiction (Foreign Corporation)

 

Technology Licensed by Foreign Corporation to the U.S. Corp. Could Suffice to Allow Jurisdictional Discovery. R & D Abroad Could Suffice as Well

 

Patent-Infringement Claims

 

L’Oréal

 

 

 

 

Appeal from the United States District Court for the District of Delaware in No. 1:17-cv-00868-CFC-SRF.

 

 

(…) UMass also challenges the district court’s personal-jurisdiction determinations. See Personal Jurisdiction Report and Recommendation at 17–26; Personal Jurisdiction Order at 1–4. Because we find that at the very least jurisdictional discovery was appropriate, we vacate and remand to the district court, without reaching the question of whether UMass made a sufficient prima facie showing that L’Oréal S.A. was subject to personal jurisdiction based on the complaint and evidence submitted at the time of the Rule 12(b)(2) motion. See Autogenomics, Inc. v. Oxford Gene Technology Ltd., 566 F.3d 1012, 1016–17 (Fed. Cir. 2009). Personal-jurisdiction analysis for patent-infringement claims is governed by Federal Circuit law. See Synthes (U.S.A.) v. G.M. Do Reis Jr. Ind. Com. de Equip. Medico, 563 F.3d 1285, 1293 (Fed. Cir. 2009); Electronics for Imaging, Inc. v. Coyle, 340 F.3d 1344, 1348 (Fed. Cir. 2003). A denial of jurisdictional discovery, however, is reviewed for abuse of discretion, applying the law of the regional circuit. Autogenomics, 566 F.3d at 1021–22. In the Third Circuit,“ if the plaintiff presents factual allegations that suggest with reasonable particularity the possible existence of the requisite contacts . . . , the plaintiff’s right to conduct jurisdictional discovery should be sustained.”  Eurofins Pharma US Holdings v. BioAlliance Pharma SA, 623 F.3d 147, 157 (3d Cir. 2010) (cleaned up and emphasis added); see also Compagnie Des Bauxites de Guinee v. L’Union Atlantique S.A. d’Assurances, 723 F.2d 357, 362 (3d Cir. 1983) (“A plaintiff who is a total stranger to a corporation should not be required, unless he has been undiligent, to try such an issue on affidavits without the benefit of full discovery.” (citation omitted)). In other words, jurisdictional discovery should be allowed unless plaintiff is attempting to “undertake a fishing expedition based only upon bare allegations” or a claim is “clearly frivolous.” Eurofins, 623 F.3d at 157; Toys “R” Us, Inc. v. Step Two, S.A., 318 F.3d 446, 456 (3d Cir. 2003) (citation omitted). Here, the district court abused its discretion in not allowing jurisdictional discovery on the record before it. In front of the magistrate judge, UMass made more than clearly frivolous, bare allegations that L’Oréal S.A. was subject to personal jurisdiction, either because L’Oréal S.A. introduced the accused products into the stream of commerce or because L’Oréal USA operated as L’Oréal S.A.’s agent in certain potentially relevant respects. See Plaintiffs’ Memorandum of Law in Opposition to Defendant L’Oréal S.A.’s Motion to Dismiss at 1–17, University of Massachusetts v. L’Oreal S.A., No. 1:17-cv-00868 (D. Del. Dec. 8, 2017), ECF No. 27. For example, as potentially relevant to both theories, UMass put forward evidence buttressing the possibility that L’Oréal S.A. researched and developed the addition of adenosine to skin-care products, J.A. 263–69; J.A. 1070; J.A. 1073–77, and L’Oréal S.A.’s own submitted declaration indicated that L’Oréal S.A. may have licensed that technology to L’Oréal USA, J.A. 553–54 (Rabinowitz Decl. ¶ 6) (“From time to time, L’Oréal S.A. and L’Oréal USA engage in the sale of goods or services between the two companies.”). For its part, L’Oréal S.A. did not specifically deny allegations that it developed and licensed the relevant technology to L’Oréal USA, stating only that “L’Oréal S.A. does not directly develop, sell, market, or advertise to consumers in Delaware any of the products at issue in this action,” without making it clear what it meant by “directly develop.” J.A. 553–54 (Rabinowitz Decl. ¶ 6).

 

 

Because this evidence raises the possibility that discovery might have uncovered the requisite contacts under our precedent, see, e.g., Nuance Communications, Inc. v. Abbyy Software House, 626 F.3d 1222, 1233–34 (Fed. Cir. 2010); Celgard, LLC v. SK Innovation Co., 792 F.3d 1373, 1379–82 (Fed. Cir. 2015), we vacate the jurisdictional determinations. UMass is entitled to jurisdictional discovery before any jurisdictional determination, if one remains necessary, is made.

 

 

 

 

 

(U.S. Court of Appeals for the Federal Circuit, June 13, 2022, University of Massachusetts v. L’Oréal S.A., Docket No. 2021-1969)

 

Tuesday, April 6, 2021

U.S. Court of Appeals for the Federal Circuit, WI-LAN INC. v. SHARP ELECTRONICS CORPORATION, Docket No. 2020-1041

 

Patent Infringement

Evidence

Discovery

Source Code Printout

Expert as a Substitute for a Fact Witness?

 

Wi-LAN Inc. appeals two related judgments of the United States District Court for the District of Delaware, on summary judgment in one instance and by stipulation in the other, holding that Sharp Electronics Corporation and Vizio, Inc. did not infringe the asserted claims of U.S. Patent No. 6,359,654 (“the ’654 patent”) and U.S. Patent No. 6,490,250 (“the ’250 patent”). We affirm.

 

(…) Here, the district court concluded that the source code printout could not be admitted under Rule 703 because it was not authenticated and, as a result, Wi-LAN was attempting to use Rule 703 as a “‘backdoor’ to allow the admission into evidence of otherwise inadmissible declarations and other materials simply because they might assist the jury’s evaluation of an expert’s opinions.” J.A. 31. We agree. Wi-LAN attempts to do exactly what is impermissible under Rule 703 by using its expert as a substitute for a fact witness to circumvent the rules of evidence to admit otherwise inadmissible evidence.

 

Wi-LAN argues that experts typically rely on material, like source code, in reaching opinions about infringement. That is obviously correct. But Wi-LAN has not made a showing that source code experts reasonably rely on unauthenticated source code printouts.

 

In light of these admissibility issues, Wi-LAN’s fallback position is that the district court should have granted it additional time to obtain an admissible version of the source code. We disagree. Wi-LAN had ample time to obtain the source code and to find custodial witnesses to authenticate the source code over the course of discovery but failed to do so.

 

Wi-LAN had been on notice since early 2016 that it was going to need the system-on-chip source code from third parties to prove its direct infringement case. Throughout the litigation, Wi-LAN repeatedly requested extensions of time to obtain the source code from the third-party manufacturers. Ultimately, however, Wi-LAN only procured a single printout version of the source code with declarations after suing the third-party manufacturers.

 

Wi-LAN, as the district court found, “had ample time and opportunities over years of litigation to obtain evidence of infringement from the system-on-chip manufacturers” but failed to do so. J.A. 32. Given this record, the district court did not abuse its discretion in denying Wi-LAN an additional opportunity to obtain an admissible form of the source code.

 

Secondary Sources: Charles Alan Wright, Arthur R. Miller & Victor J. Gold, Federal Practice and Procedure § 6274 (2d ed. 2020).

 

 

(U.S. Court of Appeals for the Federal Circuit, April 6, 2021, WI-LAN INC. v. SHARP ELECTRONICS CORPORATION, Docket No. 2020-1041)

 

 

 

Wednesday, May 1, 2019

U.S. Court of Appeals for the Federal Circuit, Thermolife International LLC, Board of Trustees of the Leland Stanford Junior University, v. GNC Corp., Docket No. 2018-1657, 2018-1666


Patent
Infringement
Adequate Pre-Suit Investigation into Infringement
Discovery
Attorney Fees Award
35 U.S.C. § 285
Enforceable Patent Rights to Research Institutions and their Exclusive Licensees


Appeals from the United States District Court for the Southern District of California in Nos. 3:13-cv-00651-JLS- MDD, 3:13-cv-00830-JLS-MDD, 3:13-cv-01015-JLS-MDD, Judge Janis L. Sammartino.

ThermoLife International, LLC exclusively licensed four patents from the Board of Trustees of the Leland Stanford Junior University. It filed infringement suits, asserting selected claims of four patents, against numerous defendants, including Hi-Tech Pharmaceuticals, Inc. and Vital Pharmaceuticals, Inc. After Stanford became a co- plaintiff of ThermoLife’s, a bench trial was held involving Hi-Tech, Vital, and a trio of companies from the GNC family as defendants (all other defendants having settled). The district court held all asserted claims invalid. That ruling ended the cases on the merits and is not at issue here.

Before us is the court’s later grant of Hi-Tech’s and Vital’s motions for attorney’s fees under 35 U.S.C. § 285, which authorizes an award of fees to a prevailing party (like Hi-Tech and Vital) in “exceptional” cases. The district court found the cases exceptional, but not based on an assessment of the validity position taken by plaintiffs ThermoLife and Stanford or how they litigated validity. Rather, the court relied on its conclusion that plaintiffs were unjustified in alleging infringement in the first place, having failed to do an adequate pre-filing investigation.

ThermoLife and Stanford appeal the district court’s award of fees, challenging the determination that these were “exceptional” cases, not the amounts the court awarded after finding the cases exceptional. We recognize that these are unusual cases in that the basis for the fee award had nothing to do with the only issues litigated to reach the judgment on the merits: Infringement had not been adjudicated in reaching the final judgment, and even discovery on infringement had been postponed early in the proceedings so that validity could be litigated first. Nevertheless, we see no abuse of discretion in the district court’s determination of exceptionality based on plaintiffs’ inadequate pre-suit investigation of infringement in these and related cases. We therefore affirm.

Stanford owns U.S. Patent Nos. 5,891,459, 6,117,872, 6,646,006, and 7,452,916, which claim methods and compositions involving the amino acids arginine and lysine, to be ingested to enhance vascular function and physical performance. See, e.g., ’459 patent, Abstract. The ’459 patent, the ’916 patent, and the relevant claims of the ’006 patent share a priority date of June 11, 1993, and expired on June 11, 2013. The ’872 patent has a priority date of June 23, 1998, and expired on June 23, 2018. All asserted claims of the ’459, ’872, and ’916 patents are method claims, whereas all asserted claims of the ’006 patent are composition claims.

(…) Pursuant to applicable local rules for patent cases, ThermoLife notified the defendants of specific infringement contentions shortly after the suits were filed. In its December 12, 2013 amended infringement contentions, ThermoLife identified specific Hi-Tech products and the corresponding allegedly infringed patent claims.

(…) By January 2014, with dozens of cases before it, the district court had set a schedule in which discovery was to begin for claim construction, invalidity, unenforceability, and standing—but not for infringement.

(…) On October 12, 2016, Hi-Tech and Vital (but not the GNC entities) moved for attorney’s fees under 35 U.S.C. § 285. Rhetoric aside, they made two related arguments for exceptionality that are relevant here. Their main argument was that plaintiffs did not conduct an adequate pre-suit investigation into infringement, an investigation that would have revealed that the accused products did not infringe claim 1 of the ’459 patent, the only claim Hi-Tech and Vital specifically discussed.

(…) In February 2018, the district court awarded $903,890.13 to Hi-Tech and $406,131.76 to Vital for attorney’s fees and expenses, including pre- and post- judgment interest.

ThermoLife and Stanford appeal the district court’s exceptional-case determination. We have jurisdiction under 28 U.S.C. § 1295(a)(1).

A court “in exceptional cases may award reasonable attorney fees to the prevailing party.” 35 U.S.C. § 285. An exceptional case is one that, under the totality of the circumstances, “stands out from others with respect to the substantive strength of a party’s litigating position” or “the unreasonable manner in which the case was litigated.” Octane Fitness, LLC v. ICON Health & Fitness, Inc., 572 U.S. 545, 554 (2014).

We conclude that the district court in this case acted within its discretion in determining, on the limited arguments plaintiffs made in response to the fee motions, that plaintiffs did not conduct an adequate pre-suit investigation into infringement by Hi-Tech and Vital. That determination would suffice to support the exceptional-case determination. And we read the district court’s additional discussion of plaintiffs’ filing of numerous suits on the patents at issue here as itself ultimately resting on the same lack of adequate pre-suit investigation, not simply on ThermoLife’s limited product sales, the expiration dates of three of the four patents, the number of suits filed, or the amounts of the settlements. For those reasons, we affirm the exceptional-case determination.

(…) The district court thus properly focused on whether, when plaintiffs sued in 2013, they had done an adequate investigation of whether the accused products were being administered in amounts that would produce the claimed effect. The district court found that one gram was needed for that purpose. That finding had adequate support in the record.

The deposition and trial testimony given by ThermoLife’s validity expert provides such support. In the deposition, the expert described knowledge available before the 2013 filing of these cases (…).

All the studies that were performed after Dr. Cooke’s initial study and that showed an increase in nitric oxide utilized doses higher than 1.5 to 2 grams per day in a chronic dosing, whereas several studies that have been published and claimed that L-arginine is ineffective in increasing nitric oxide were using doses of 1 to 1.5 grams and below.

(…) J.A. 10456. Asked “you said showed 1 gram was ineffective; is that correct?,” he replied, “1 gram and below was ineffective.” Id. “Q: According to studies? A: Yes.” Id. At trial, he was asked: “And administering 1 gram or less of a supplement is not going to affect the arginine—excuse me, is not going to meaningfully affect the arginine level in one’s plasma, correct?” J.A. 10463. He answered: “That’s correct.” Id. The district court committed no clear error in finding one gram necessary for the claimed efficacy.

Finally, given this evidence, we see no error in the district court’s attribution to plaintiffs of knowledge of the one-gram minimum. Their expert testified that this minimum was revealed in the public literature. It is not an abuse of discretion in these circumstances to fault plaintiffs for failing to learn this public-literature information before bringing suit, whether by hiring an expert or otherwise.

The district court also committed no reversible error in determining that plaintiffs did not conduct adequate investigations to apply the one-gram minimum to the accused products. Importantly, it was not disputed in the district court that “all the relevant products were publicly available.” Fees Op., 2017 WL 1235766, at *5. Nor was it disputed that plaintiffs could have determined the amounts of L-arginine or its hydrochloride salt (in the recommended servings of the accused products) by performing what Vital characterized as a “simple test.” J.A. 10537; see also J.A. 10710 (Hi-Tech’s motion). Nor, finally, does the record reveal that plaintiffs performed such a test.

We have explained that testing of an accused product is not necessarily a required part of an adequate pre-filing investigation. See Intamin Ltd. v. Magnetar Techs., Corp., 483 F.3d 1328, 1338 (Fed. Cir. 2007) (testing not required where high obstacles to testing); Q-Pharma, Inc. v. Andrew Jergens Co., 360 F.3d 1295, 1302−03 (Fed. Cir. 2004) (testing unnecessary for purposes of Rule 11 and § 285 where the product labels, among other things, supported infringement). Whether testing is necessary for a responsible accusation of infringement necessarily depends on the availability of the products at issue, the existence and costs of testing, and whether other sufficiently reliable information exists. Here, given the deficiencies of the two possible alternatives to testing (product label ingredient lists and product advertising), we see no error in the district court’s determination that this matter was one in which there was no adequate substitute for simple testing of publicly available products.

The district court noted that there was some, though slim, evidence that plaintiffs examined the labels of the accused products. Fees Op., 2017 WL 1235766, at *5; Reconsideration Op., 2017 WL 4792426, at *6; see J.A. 10187 (deposition testimony of ThermoLife’s president). But the court agreed with Vital and Hi-Tech that the labels of at least some, perhaps many, of the accused products made clear that they did not contain one gram of L-arginine or its hydrochloride salt in a serving. Fees Op., 2017 WL 1235766, at *5–7. The evidence supports that determination.

The label of Vital’s NO Synthesize does not list L-arginine or its hydrochloride salt as an ingredient at all. J.A. 10509.9 The labels of other accused products list L-arginine but in amounts that preclude one gram per serving.

Had plaintiffs investigated, they might have found, as stated in Vital’s evidence credited by the district court, that the amount was less than 5 milligrams per serving. See Fees Op., 2017 WL 1235766, at *6 (citing J.A. 11586).

(…) Those deficiencies in labels either preclude an accusation of infringement or, at a minimum, strongly suggest a need for testing.

(…) Ingredient lists on the labels aside, plaintiffs also relied for their pre-filing investigation on what may be described as advertising by the defendants for their products—including the non-ingredient portions of labels. In some circumstances, a potential infringer’s public assertions about its products may supply, or help to supply, a reliable basis for a patent owner to allege infringement. See Q-Pharma, 360 F.3d at 1302−03 (“Because Q-Pharma obtained a sample of the accused product, reviewed Jergens’ statements made in the advertising and labeling of the accused product, and, most importantly, compared the claims of the patent with the accused product, we conclude that its claim of infringement was supported by a sufficient factual basis.”). But the nature and setting of the assertions can significantly affect their reliability for that purpose. Here, the district court properly found that defendants’ advertising claims were no substitute for simple testing.

(…) The patent statute does not restrict enforceable patent rights to those who practice the patent, to the exclusion of research institutions and their exclusive licensees engaged to perform needed enforcement activities in which the inventors, or research institutions, may lack expertise or experience. See Continental Paper Bag Co. v. Eastern Paper Bag Co., 210 U.S. 405, 424−25 (1908); Broadcom Corp. v. Qualcomm Inc., 543 F.3d 683, 703 (Fed. Cir. 2008); Rite-Hite Corp. v. Kelley Co., Inc., 56 F.3d 1538, 1547 (Fed. Cir. 1995); cf. eBay Inc. v. MercExchange, L.L.C., 547 U.S. 388, 393 (2006) (rejecting categorical exclusion of non-practitioners from injunctive remedy).


(U.S. Court of Appeals for the Federal Circuit, May 1, 2019, Thermolife International LLC, Board of Trustees of the Leland Stanford Junior University, v. GNC Corp., Docket No. 2018-1657, 2018-1666)

Friday, February 20, 2015

U.S. Court of Appeals for the DC Circuit, FTC v. Boehringer Ingelheim Pharmaceuticals, Inc.


Antitrust: evidence: discovery: work product doctrine: opinion product doctrine: attorney-client privilege:

The FTC issued an administrative subpoena seeking various documents. Boehringer withheld hundreds of responsive documents under the work product doctrine and the attorney-client privilege. After the FTC objected, the District Court reviewed in camera a sample of the contested documents, and found that almost all were properly withheld under the work product doctrine or the attorney-client privilege. On appeal, the FTC challenges the District Court’s application of the work product doctrine.

The FTC argues that the District Court committed legal error by applying an overly expansive definition of “opinion” work product, which is highly protected, as opposed to “fact” work product, which is substantially less so. Because we agree that the District Court misapprehended the proper distinction between fact and opinion work product, we reverse and remand on this issue.

Boehringer manufactures Aggrenox and Mirapex, two patented pharmaceutical drugs that earn hundreds of millions of dollars in U.S. sales each year. In 2005, Barr sought and received FDA approval to market generic versions of these drugs, which led Boehringer to sue Barr for patent infringement. See Boehringer Ingelheim Int’l GmbH v. Barr Labs. Inc., Civ. Action No. 05-700-JJF (D. Del. filed Sept. 26, 2005). Barr, in turn, contended that Boehringer’s patents were invalid. While the Delaware litigation was pending, Boehringer and Barr entered into settlement negotiations. Boehringer’s senior vice president and general counsel, Marla Persky, served as its lead negotiator during these discussions. FTC Investig. Hr’g Tr. at 70-71, J.A. 755-56. To this end, Persky and her staff engaged in both legal and business activities, including evaluating possible litigation outcomes, considering potential antitrust concerns, and evaluating and negotiating the business terms of the settlement. Id. at 113-16, 118, 120-23, J.A. 772-80.

On August 11, 2008, the two companies settled their dispute on the following terms: Barr would refrain from marketing its generic versions of Aggrenox and Mirapex in the immediate future, but Boehringer would permit Barr to enter the market several months ahead of the expiration of Boehringer’s patents. Boehringer, 286 F.R.D at 105; see also Aggrenox Settlement Agreement, J.A. 871-83; Press Release, J.A. 886-88. In the meantime, under a related co-promotion agreement, Barr would help Boehringer promote Aggrenox to medical professionals in exchange for certain specified fees and royalties on Aggrenox sales. Boehringer, 286 F.R.D at 105; see also Co-Promotion Agreement, J.A. 889-930.

While this type of settlement deal is not necessarily unlawful, see FTC v. Actavis, Inc., 133 S. Ct. 2223, 2237-38 (2013), such a settlement may be subject to antitrust scrutiny if it appears that the patent-holding firm – here, Boehringer – was using the co-promotion agreement as a vehicle to avoid legitimate competition. Id. at 2236-37. And, indeed, the specific terms of this settlement raised the suspicions of the FTC that Boehringer was simply paying Barr off in order to delay the entry of generics into the market. Boehringer, 286 F.R.D at 105. The FTC initiated an investigation and served Boehringer with a subpoena duces tecum. Id. After Boehringer failed to meet a deadline for production, the FTC filed a petition in district court for an order enforcing the subpoena. Id.

Appellant’s Br. 12-16: limiting challenge on appeal to financial documents analyzing litigation settlement and co-promotion agreement.

By agreement of the parties, Boehringer submitted a sample set of documents in camera to the District Court. Boehringer, 286 F.R.D at 106. After reviewing the documents, the District Court issued a decision largely upholding Boehringer’s work product claims. (see FED. R. CIV. P. 26(b)(3) (protecting from disclosure materials “prepared in anticipation of litigation”)).

We review a district court’s decision to enforce an administrative subpoena for abuse of discretion. See U.S. Int’l Trade Comm’n v. ASAT, Inc., 411 F.3d 245, 253 (D.C. Cir. 2005). A district court necessarily abuses its discretion if it applies the incorrect legal standard, a question that is reviewed de novo. See Conservation Force v. Salazar, 699 F.3d 538, 542 (D.C. Cir. 2012); FTC v. Church & Dwight Co., 665 F.3d 1312, 1315 (D.C. Cir. 2011). A district court’s factual findings are reviewed for clear error. Boca Investerings P’ship v. United States, 314 F.3d 625, 629 (D.C. Cir. 2003). A finding is clearly erroneous, even where there is record evidence to support it, if “the reviewing court on the entire record is left with the definite and firm conviction that a mistake has been committed.” Awad v. Obama, 608 F.3d 1, 6-7 (D.C. Cir. 2010).

The Supreme Court first articulated the federal work product doctrine in Hickman v. Taylor, 329 U.S. 495 (1947), where it was asked to define the reach of the pre-trial deposition and discovery mechanisms established by the then-new Federal Rules of Civil Procedure. These rules, which required each party “to disgorge whatever [relevant, non-privileged] facts he has in his possession,” dramatically expanded the scope of pre-trial discovery. Id. at 507. Under a literal reading of the Rules, a party would be entitled to discover any non-privileged trial preparation materials, such as attorney notes from witness interviews, created by his opponent in that litigation. See id. at 506.

The Supreme Court rejected this literal reading, holding that compelled disclosure of attorney work product would “contravene the public policy underlying the orderly prosecution and defense of legal claims.” Id. at 510. The Court explained that in performing one’s duties as a lawyer (…) it is essential that a lawyer work with a certain degree of privacy, free from unnecessary intrusion by opposing parties and their counsel. Proper preparation of a client’s case demands that he assemble information, sift what he considers to be the relevant from the irrelevant facts, prepare his legal theories and plan his strategy without undue and needless interference. Id. at 510-11. Readily compelling the disclosure of such work product to opposing counsel would lead to “inefficiency, unfairness and sharp practices.” Id. at 511. Hickman clarified that discovery of an attorney’s work materials was permitted only in limited circumstances. Id. A party seeking such materials must establish “adequate reasons to justify production through subpoena or court order,” and even then, discovery is limited to “relevant and non-privileged facts.” Id. at 511-12.

Hickman was later codified in substantial part in Rule 26(b)(3) of the Federal Rules. Rule 26 provides that a party generally may not discover “documents and tangible things that are prepared in anticipation of litigation or for trial by or for another party or its representative.” FED. R. CIV. P. 26(b)(3)(A). Such discovery is permissible, however, if “the party shows that it has substantial need for the materials to prepare its case and cannot, without undue hardship, obtain their substantial equivalent by other means,” so long as counsel’s “impressions, conclusions, opinions, or legal theories” are not disclosed. FED. R. CIV. P. 26(b)(3)(A)-(B); see FED. R. CIV. P. 81(a)(5) (providing that the Federal Rules apply to proceedings to enforce an administrative subpoena).

The work product protection is broader than the attorney-client privilege in that it is not restricted solely to confidential communications between an attorney and client. In re Sealed Case, 676 F.2d 793, 808-09 (D.C. Cir. 1982). It is narrower, however, insofar as the doctrine protects only work performed in anticipation of litigation or for trial. See Senate of Puerto Rico v. Dep’t of Justice, 823 F.2d 574, 586 (D.C. Cir. 1987) (“The work product doctrine does not extend to every written document generated by an attorney . . . rather, work product covers only documents prepared in contemplation of litigation”). A document prepared as work product for one lawsuit will retain its protected status even in subsequent, unrelated litigation. See FTC v. Grolier Inc., 462 U.S. 19, 27-28 (1983); In re Murphy, 560 F.2d 326, 333-35 (8th Cir. 1977) (holding that materials prepared for patent settlement retained work product protection in subsequent antitrust litigation).

The FTC does not challenge the District Court’s ruling that documents created by Boehringer for the purpose of settling the patent infringement litigation are protected work product. It takes issue, however, with the District Court’s finding that the materials relating to the co-promotion agreement fall within the category of protected settlement documents.

We find no merit in the proposition that any settlement term that has some independent economic value to both parties must always be treated as an ordinary (non-litigation) business transaction for purposes of work product protection. Common sense and practical experience teach that settlement deals routinely include arrangements that could be isolated from the overall agreement and stand on their own but were nonetheless crafted for the purpose of settling litigation. Indeed, the Supreme Court’s refusal in Actavis to hold reverse payment settlement agreements presumptively unlawful anticipates that a reverse payment could “represent payment” for “other services” aside from a party’s agreement to end litigation yet still be part of the settlement. 133 S. Ct. at 2237.

Upon our review of the record, we find no clear error in the District Court’s factual finding that the co-promotion agreement was “integral” to the broader settlement. Boehringer, 286 F.R.D. at 109. Accordingly, the District Court did not err in drawing the legal conclusion that the co-promotion agreement materials were prepared “in anticipation of” the patent litigation and were therefore entitled to work product protection.

Because we find that the documents are protected, we do not reach Boehringer’s alternative argument that the co-promotion agreement materials are protected because counsel used them to evaluate potential antitrust liability. 

When a factual document selected or requested by counsel exposes the attorney’s thought processes and theories, it may be appropriate to treat the document as opinion work product, even though the document on its face contains only facts. See Dir., Office of Thrift Supervision v. Vinson & Elkins, LLP, 124 F.3d 1304, 1308 (D.C. Cir. 1997) (“At some point . . . a lawyer’s factual selection reflects his focus; in deciding what to include and what to omit, the lawyer reveals his view of the case.”). At the same time, however, “not every item which may reveal some inkling of a lawyer’s mental impressions . . . is protected as opinion work product.” In re San Juan Dupont Plaza Hotel Fire Litig., 859 F.2d 1007, 1015 (1st Cir. 1988). Opinion work product protection is warranted only if the selection or request reflects the attorney’s focus in a meaningful way. See Dir., Office of Thrift Supervision, 124 F.3d at 1308; In re San Juan Dupont Plaza Hotel Fire Litig., 859 F.2d at 1015 (heightened protection is triggered only if “disclosure creates a real, nonspeculative danger of revealing the lawyer’s thoughts”). And where a document contains both opinion and fact work product, the court must examine whether the factual matter may be disclosed without revealing the attorney’s opinions.

In Sealed Case (1997), for example, we held that attorney notes of preliminary interviews with a witness were not necessarily opinion work product, as the mere fact that an attorney had chosen to write a fact down was not sufficient to convert that fact into opinion work product. 124 F.3d at 236-37. Rather, there must be some indication that the lawyer “sharply focused or weeded the materials.” Id. at 236.

Where an attorney’s mental impressions are those that “a layman would have as well as a lawyer in these particular circumstances, and in no way reveal anything worthy of the description ‘legal theory,’” those impressions are not opinion work product. In re HealthSouth Corp. Sec. Litig., 250 F.R.D. 8, 11 (D.D.C. 2008) (quoting In re John Doe Corp., 675 F.2d 482, 493 (2d Cir. 1982)).

A party’s ability to discover work product often turns on whether the withheld materials are fact work product or opinion work product. A party generally must make an “extraordinary showing of necessity” to obtain opinion work product. In re Sealed Case, 676 F.2d at 811; see also Dir., Office of Thrift Supervision, 124 F.3d at 1307 (observing that opinion work product is “virtually undiscoverable”). By contrast, “to the extent that work product contains relevant, nonprivileged facts,” the work product doctrine “merely shifts the standard presumption in favor of discovery and requires the party seeking discovery to show ‘adequate reasons’ why the work product should be subject to discovery.” In re Sealed Case, 676 F.2d at 809 (quoting Hickman, 329 U.S. at 512). This “adequate reasons” test corresponds to Rule 26(b)(3)’s requirement, adopted in 1970, that a party seeking fact work product demonstrate that “it has substantial need for the materials to prepare its case and cannot, without undue hardship, obtain their substantial equivalent by other means.” FED. R. CIV. P. 26(b)(3)(A)(ii); see In re Sealed Case, 676 F.2d at 809 n.59.

The meaning of Rule 26(b)(3)’s “substantial need” requirement is not clear from the plain language of the rule. Cf. Pierce v. Underwood, 487 U.S. 552, 563-64 (1988) (discussing the ambiguity implicit in the term “substantial” while interpreting 28 U.S.C. § 2412(d)(1)(A)); see also A.I.A. Holdings, S.A. v. Lehman Bros., Civ. Action No. 97-4978, 2000 WL 1639417, at *2 (S.D.N.Y. Nov. 1, 2000) (noting that “the law is not well developed as to what constitutes ‘substantial need’”); Special Project, The Work Product Doctrine, 68 CORNELL L. REV. 760, 802 (1983) (“The substantial need requirement is the least uniformly applied by the courts.”). Helpfully, the Advisory Committee’s notes on the amendments “provide a reliable source of insight into the meaning of a rule, especially when, as here, the rule was enacted precisely as the Advisory Committee proposed.” United States v. Vonn, 535 U.S. 55, 64 n.6 (2002) (interpreting FED. R. CRIM. P. 11(h)).

The “substantial need” and “undue hardship” requirements were added to Rule 26(b)(3) in an attempt to clarify and codify the tests developed by the Supreme Court in Hickman and by the lower courts construing former Rule 34’s “good cause” provision. See FED. R. CIV. P. 26(b)(3) advisory committee’s note to 1970 Amendments (hereinafter Advisory Committee’s Notes), reproduced at 48 F.R.D. 487, 500-01; see also In re Sealed Case, 676 F.2d at 810 n. 59; WRIGHT ET AL., supra, § 2023, at 489 (characterizing Rule 26(b)(3) as “a largely accurate codification of the doctrine announced in the Hickman case and developed in later cases in the lower courts”). The Committee explained that the amendments were intended to require an inquiry into “the importance of and need for” the fact work product at issue, as well as “alternative sources for securing the same information.” Advisory Committee’s Notes, 48 F.R.D. at 500. The Committee did not further define the “substantial need” and “undue hardship” concepts.

The Committee did provide guidance, however, by pointing to four cases that had demanded a “special showing” to obtain trial preparation materials; it explained that the new “substantial need” and “undue hardship” requirements reflected the holdings of those cases. Id. (citing Guilford Nat’l Bank v. Southern Ry., 297 F.2d 921 (4th Cir. 1962); Mitchell v. Bass, 252 F.2d 513 (8th Cir. 1958); Hauger v. Chicago, R.I. & Pac. R.R., 216 F.2d 501 (7th Cir. 1954); Burke v. United States, 32 F.R.D. 213 (E.D.N.Y. 1963)). The Committee also approved of a list of circumstances under which witness statements could be discoverable, as recited in a fifth case, Southern Ry. v. Lanham, 403 F.2d 119 (5th Cir. 1968). Advisory Committee’s Notes, 48 F.R.D. at 501.

(The 1970 amendments abolished the distinction between factual materials prepared by counsel and those prepared by non-attorneys. FED. R. CIV. P. 26(b)(3)(A); see Nobles, 422 U.S. at 254 n.16).

These cases indicate that a moving party’s burden is generally met if it demonstrates that the materials are relevant to the case, the materials have a unique value apart from those already in the movant’s possession, and “special circumstances” excuse the movant’s failure to obtain the requested materials itself. See Mitchell, 252 F.2d at 518-19 (permitting discovery of opponent’s witness statements where witnesses refused to speak with movant); Burke, 32 F.R.D. at 215 (permitting discovery of accident report materials where information contained therein was otherwise unavailable); cf. Hauger, 216 F.2d at 505-06 (finding no “special circumstances” warranting disclosure of witness statements where plaintiff had deposed those same witnesses, and plaintiff’s purported need for materials for purposes of impeachment was speculative); Guilford, 297 F.2d at 923-27 (finding no “special circumstances” where plaintiff possessed substantially similar materials and impeachment value was speculative). A list of special circumstances was provided in Lanham, where the Fifth Circuit observed that a contemporaneous witness statement typically would be discoverable if the witness was unavailable, reluctant, or hostile, or if the witness had a lapse of memory or deviated from prior statements. 403 F.2d at 128-31.

Although each of these cases mentioned the relevance of the requested documents, none articulated a requirement that the documents be essential to the claim or probative of a critical element. The Advisory Committee notably did not cite any of the then-existing decisions demanding a heightened showing of relevance. Compare Republic Gear Co. v. Borg-Warner Corp., 381 F.2d 551, 558 (2d Cir. 1967) (requiring party seeking fact work product to demonstrate that the documents were “essential to the preparation of [movant’s] case on a critical issue” in the litigation). Boehringer’s argument that factual work product is discoverable only if it contains a “smoking gun” therefore has no basis in the Committee notes or the cases cited therein.

Of course, this interest in liberal discovery must be balanced against the key goal underlying the protection for fact work product: that each side must undertake its own investigation of the relevant facts and not simply freeload on opposing counsel. See Guilford, 297 F.2d at 926 (work product rule serves to prevent a less-than-diligent litigant from “performing its functions either without wits or on wits borrowed from the adversary”) (quoting Hickman, 329 U.S. at 516 (Jackson, J., concurring)); Nat’l Union Fire Ins. v. Murray Sheet Metal Co., Inc., 967 F.2d 980, 985 (4th Cir. 1992). But neither of these competing interests is served when unique, relevant information is withheld from a party that never had an opportunity to obtain the information on its own. The “substantial need” inquiry requires a careful examination of whether non-disclosure will impair the truth-seeking function of discovery. See Dir., Office of Thrift Supervision, 124 F.3d at 1308 (finding no substantial need for fact work product where movant already possessed similar materials). A moving party need not show, however, that the requested documents are critical to, or dispositive of, the issues to be litigated.


Books: CHARLES ALAN WRIGHT ET AL., FEDERAL PRACTICE & PROCEDURE § 2024, at 502 (3d ed. 2010) ; JAMES WM. MOORE ET AL., MOORE’S FEDERAL PRACTICE § 26.70[5][c], at 26-457 to 26-459 (3d ed. 2009). 


(U.S. Court of Appeals for the DC Circuit, Feb. 20, 2015, FTC v. Boehringer Ingelheim Pharmaceuticals, Inc., No. 12-5393, Circuit Judge Wilkins).


Preuves : documents dont la production ne peut pas être exigée, car au bénéfice d’un privilège, soit de confidentialité (« opinion product doctrine »), soit de contenu (« work product doctrine ») :

Dans ce cas de droit des cartels jugé par le 2è Circuit fédéral, la FTC avait ordonné la production par B. d’un certain nombre de pièces. B. refusa la production, invoquant les deux privilèges précités. Saisie, la cour de district fédérale procéda hors la présence des parties à la révision de ces documents, les jugeant après examen couverts par les privilèges. La FTC déposa un recours devant la présente Cour d’appel.

La confidentialité sous l’angle d’ »opinion product » est plus étendue que sous l’angle «work product ».

En l’espèce, un fabricant de médicaments a obtenu l’autorisation de commercialiser sous forme générique deux médicaments encore vendus par le titulaire du brevet. Le titulaire actionna en violation du brevet. L’entreprise générique argua de la nullité du brevet. Pendant la procédure, des discussions transactionnelles débutèrent, dirigées par la responsable du service juridique du côté de l’entreprise titulaire du brevet.

La négociation a abouti : l’entreprise générique s’est engagée à ne pas commercialiser son produit dans un futur immédiat, et l’entreprise titulaire du brevet autorisa son adverse partie à entrer dans le marché quelques mois avant l’expiration du brevet. Par ailleurs, pendant cette période transitoire de quelques mois, l’entreprise générique s’est engagée à aider l’entreprise titulaire à faire la promotion du médicament, moyennant rémunération dépendante du succès des ventes.

Ce type d’arrangement n’est pas en soi illégal, mais selon la jurisprudence Actavis (2013, Cour Suprême fédérale), sa conformité au droit fédéral des cartels doit être évaluée s’il apparaît que l’entreprise titulaire du brevet utilise l’accord de co- promotion comme moyen d’éviter une concurrence légitime. Et en l’espèce, les termes de l’accord ont fait craindre à la FTC que l’entreprise titulaire ne faisait rien d’autre que payer sa concurrente pour retarder l’entrée des génériques sur le marché.

La FTC initia une enquête et notifia à B, entreprise titulaire du brevet, une ordonnance en production de documents. B n’a rien produit dans les délais, de sorte que la FTC déposa une requête devant la cour de district fédérale, sollicitant une ordonnance d’exécution.

En l’espèce, ne reste litigieux que le sort de la production de documents financiers qui analysent un accord en procédure ainsi qu’un accord de co-promotion.

D’entente entre parties, B. soumit à la cour de district, statuant hors la présence des parties, un exemplaires des documents précités. Après examen, la cour rendit une décision reprenant largement la position de B., fondée sur l’argument du « work product » (qui protège de la divulgation les éléments préparés en prévision d’un litige).

La présente Cour revoit sous l’angle de l’abus du pouvoir de discrétion une décision d’une cour de district se prononçant sur la question de l’exécution d’une requête administrative en production de documents. L’abus du pouvoir de discrétion est donné si la cour de district a appliqué une théorie juridique incorrecte, question revue avec un pouvoir d’examen complet. Les constatations de la cour de district portant sur les faits sont revues sous l’angle de l’erreur manifeste (« clear error »).

La Cour Suprême fédérale caractérisa pour la première fois la doctrine de « federal work product » dans sa décision Hickman (1947), dans le cadre de la détermination de l’étendue des mécanismes de la procédure de « discovery » et de dépositions avant procès tels que mis en place par les nouvelles Règles fédérales de procédure civile. Ces Règles, qui permettaient d’exiger de chaque partie la production de tous les éléments relevants, en leur possession, qui n’étaient pas privilégiés, étendirent substantiellement les possibilités de « discovery » avant procès (rendant par exemple possible d’obtenir le dépôt au dossier des notes de l’avocat prises à l’occasion de l’interrogatoire d’un témoin avant procès).

La Cour Suprême fédérale rejeta toutefois une lecture aussi large des Règles, jugeant que contraindre la production du travail de l’avocat, sans distinction, serait contraire à la notion d’ordre public qui sous-tend l’instruction ordonnée d’un procès civil et la défense dans ce procès. La Cour précisa que dans l’accomplissement de ses tâches, il est essentiel que l’avocat puisse travailler avec une certaine marge de confidentialité, libre d’intrusions sans nécessité de l’adverse partie. Hickman précisa ainsi que la production, par la procédure de « discovery », du produit du travail de l’avocat, ne pouvait être permis que dans des circonstances limitées.  Celui qui recherche la production comme moyen de preuve du produit du travail de l’avocat doit établir des raisons adéquates, et la production ne sera pas ordonnée pour ce qui est du travail qualifié de privilégié.

La jurisprudence Hickman a été ultérieurement codifiée dans la Règle 26(b)(3) des Règles fédérales de procédure civile. Cette règle prévoit que de manière générale une partie ne peut pas obtenir la production de documents ou de choses préparées en anticipation d’une procédure. La production sera cependant possible si la partie qui la requiert démontre qu’elle en a un besoin substantiel pour préparer son dossier judiciaire et qu’elle ne peut pas, sans une peine qui ne saurait être exigée d’elle, obtenir un équivalent substantiel par d’autres moyens. Mais même dans cette situation, les impressions, les conclusions, les avis et les théories juridiques d’un avocat seront toujours retranchés de la production. Il est ici en outre rappelé que la Règle 81(a)(5) prévoit l’application des Règles de procédure civile aux procédures d’exécution d’une ordonnance administrative de production.

La protection accordée au « work product » est plus large que la protection accordée par l’ »attorney-client privilege », en ce qu’elle n’est pas restreinte seulement aux communications confidentielles entre un avocat et son client. Elle est cependant plus restreinte en ce qu’elle ne protège que le travail entrepris en anticipation d’un procès ou entrepris pour le procès lui-même. Un document préparé en tant que « work product » pour une procédure conservera par la suite son statut protégé, même dans le cadre d’une procédure ultérieure sans rapport avec la procédure antérieure.

Quand un document dont la production est requise expose le processus de réflexion d’un avocat et les théories juridiques qu’il envisage, il peut être approprié de traiter ce document comme relevant de l’ »opinion work product », même si ce document ne contient que des faits. A un certain point, la sélection des faits opérée par l’avocat reflète ses centres de réflexion. Mais la protection de l’ »opinion work product » ne sera accordée que si le document requis reflète de manière significative les points d’intérêts que l’avocat a retenu dans sa réflexion.

La jurisprudence de la présente Cour a précisé que les notes de l’avocat relatives à des entretiens préliminaires avec un témoin ne relevaient pas nécessairement de l’ »opinion work product ». Pour être ainsi protégées, les notes doivent contenir une indication que l’avocat accorde une importance particulière à ce qu’il a écrit.

Quand les notes de l’avocat reflètent les réflexions qu’un profane lui-même aurait pu mener dans des circonstances semblables, et que ces notes ne méritent pas la qualification de théorie juridique, elles ne sauraient être protégées par la notion d’ »opinion work product ».

De manière générale, une partie doit procéder à une démonstration extraordinaire de nécessité pour obtenir des pièces relevant de l’ »opinion work product ». Une jurisprudence a même indiqué que l’ »opinion work product » était pour ainsi dire hors d’atteinte en procédure de « discovery ». Par contraste, dans la mesure où le « work product » contient des faits relevants et non privilégiés, la doctrine du « work product » renverse la présomption standard en faveur de la production et exige de la partie qui la demande de démontrer des raisons adéquates justifiant la production. Ce test des raisons adéquates correspond à la Règle 26(b)(3), adoptée en 1970, exigeant d’une partie qui demande la production de « fact work product » la démonstration d’un besoin substantiel des pièces visées pour la préparation de la procédure, et la démonstration que des moyens de preuves équivalents ne peuvent être obtenus par ailleurs sans la mise en œuvre de procédés hors proportion.

Il est à remarquer que la notion de » besoin substantiel » posée par la Règle 26(b)(3) n’est pas claire à la lecture de son texte seul. Une contribution doctrinale de 1983 relève que la condition de besoin substantiel constitue la notion  bénéficiant de la considération la moins uniforme de la part des Tribunaux. Mais les remarques de l’ »Advisory Committee » sur la Règle procurent un éclairage utile, surtout considérant que la Règle a été édictée telle que proposé par ce Comité.

Selon les notes de l’ »Advisory Committee », les exigences de « besoin substantiel » et de « procédés hors proportion » ont été ajoutées à la Règle 26(b)(3) comme un moyen de clarifier et de codifier les tests développés par la Cour Suprême fédérale dans sa décision Hickman et par les cours inférieures dans leurs interprétations de la notion de « bonnes raisons » stipulées dans l’ancienne Règle 34. Le Comité a exposé que le but de ces amendements était de provoquer une instruction portant sur l’importance et le besoin des « fact work product »sollicités et portant sur l’existence de moyens alternatifs permettant de se procurer ces preuves. Cependant, le « Committee » n’a pas défini davantage les concepts de « besoin substantiel » et de « procédés hors proportion ».

Mais le « Committee » a toutefois apporté quelques lumières sur ces concepts en se référant à cinq décisions de justice qui avaient demandé une démonstration spéciale pour obtenir des pièces établies en préparation de la procédure. Il a précisé que les deux concepts précités étaient définis par ces décisions.

Par amendements de 1970 aux Règles, la distinction entre le produit du travail de l’avocat et le produit du travail d’un assistant qui n’est pas avocat a été abolie (cf. Règle fédérale de procédure civile 26(b)(3)(A)).

Les cinq jurisprudences précitées indiquent que celui qui sollicite la production des pièces obtiendra généralement gain de cause s’il démontre que ces pièces sont relevantes pour son dossier, qu’elles ont une valeur unique que n’a pas les pièces déjà en sa possession, et que des circonstances spéciales excusent l’échec du requérant à les obtenir par lui-même. Par exemple, la production de la déposition d’un témoin adverse a été ordonnée quand le témoin refusait de déposer devant le requérant.

Chacune de ces jurisprudences a mentionné la relevance comme l’un des critères permettant la production. Aucune d’elles n’impose que la pièce sollicitées soient essentielles à la prétention déduite en justice. Aucune d’elles n’impose une valeur probante particulière de la pièce requise.

Bien entendu, cette conception libérale de la pratique de la procédure de « discovery » doit être balancée avec le but de la protection des « fact work product » : chaque partie doit entreprendre ses propres investigations portant sur les faits relevants, et ne peut simplement se reposer sur le travail de l’adversaire. La condition de « besoin substantiel » exige d’examiner attentivement si la non-production aurait pour conséquence de porter atteinte à la fonction de recherche de la vérité, fonction qui est celle de la procédure de « discovery ».






Monday, June 16, 2014

Republic of Argentina v. NML Capital, Ltd., Docket 12-842



Immunity: of a foreign state, postjudgment immunity, discovery: after petitioner, Republic of Argentina, defaulted on its external debt, respondent, NML Capital, Ltd. (NML), one of Argentina’s bondhold­ers, prevailed in 11 debt-collection actions that it brought against Ar­gentina in the Southern District of New York. In aid of executing the judgments, NML sought discovery of Argentina’s property, serving subpoenas on two nonparty banks for records relating to Argentina’s global financial transactions.
Held: No provision in the FSIA (Foreign Sovereign Immunities Act of 1976)  immunizes a foreign-sovereign judg­ment debtor from postjudgment discovery of information concerning its extraterritorial assets.
This Court assumes without deciding that, in the ordinary case, a district court would have the discretion under Federal Rule of Civil Procedure 69(a)(2) to permit discovery of third-party information bearing on a judgment debtor’s extraterritorial assets.
The FSIA replaced an executive-driven, factor-intensive, loosely common-law-based immunity regime with “a comprehensive frame­work for resolving any claim of sovereign immunity.” Republic of Austria v. Altmann, 541 U. S. 677, 699. Henceforth, any sort of im­munity defense made by a foreign sovereign in an American court must stand or fall on the Act’s text. The Act confers on foreign states two kinds of immunity. The first, jurisdictional immunity (28 U. S. C. §1604), was waived here. The second, execution immunity, generally shields “property in the United States of a foreign state” from attachment, arrest, and execution. §§1609, 1610. See also §1611(a), (b)(1), (b)(2). The Act has no third provision forbidding or limiting discovery in aid of execution of a foreign-sovereign judgment debtor’s assets. Far from containing the “plain statement” necessary to preclude application of federal discovery rules, Société Nationale Industrielle Aérospatiale v. United States Dist. Court for Southern Dist. of Iowa, 482 U. S. 522, 539, the Act says not a word about postjudgment discovery in aid of execution.
Argentina’s arguments are unavailing. Even if Argentina were correct that §1609 execution immunity implies coextensive discovery ­in-aid-of-execution immunity, the latter would not shield from dis­covery a foreign sovereign’s extraterritorial assets, since the text of §1609 immunizes only foreign-state property “in the United States.” The prospect that NML’s general request for information about Ar­gentina’s worldwide assets may turn up information about property that Argentina regards as immune does not mean that NML cannot pursue discovery of it (U.S.S.Ct., 16.06.2014, Republic of Argentina v. NML Capital, Ltd., Docket 12-842, J. Scalia).

Immunité d’un état étranger, de manière générale et après jugement condamnatoire en particulier, au stade de l’exécution forcée du jugement : un détenteur de bons du trésor d’un état étranger obtient gain de cause au fond devant un Tribunal fédéral de district de l’état de New York. Comme aide à l’exécution des jugements, le créancier dépose une requête en discovery portant sur les biens de l’état défaillant, en faisant délivrer des ordres de production, à des banques tierces, de dossiers liés aux transactions financières globales de l’état étranger.
La Cour juge qu’aucune disposition de la loi fédérale de 1976 sur l’immunité des états étrangers ne prohibe un créancier qui a obtenu gain de cause au fond de déposer une requête en discovery, portant sur des biens situés hors du territoire des Etats-Unis, dans le cadre de l’exécution du jugement condamnatoire rendu en défaveur de l’état étranger.
La Cour assume, sans toutefois en juger, que dans un cas ordinaire, une cour de district fédérale peut autoriser, de manière discrétionnaire, en application de la Règle 69(a)(2) de procédure civile fédérale, en exécution d’un jugement, la discovery d’informations en mains de tiers portant sur les biens du débiteur, biens situés hors du territoire des Etats-Unis.
La loi de 1976 précitée constitue un cadre compréhensif et exhaustif pour résoudre toutes les défenses basées sur l’invocation de l’immunité. Il se substitue à la Common law antérieure régissant cette matière. La loi confère aux états étrangers deux types d’immunité. En l’espèce, l’état étranger a renoncé à se prévaloir de la première, l’immunité de juridiction. La seconde, l’immunité d’exécution, protège de toutes formes de saisie la propriété de l’état étranger sur sol des Etats-Unis. La loi ne contient pas de troisième disposition interdisant ou limitant la discovery portant sur des biens et intervenant dans l’exécution d’un jugement perdu par un état étranger.